Main Disclosure – Disinvestment Details

Target Entity: Pivot Path Private Limited

Percentage Stake Disinvested: Majority stake (exact percentage not specified, but resulting holding drops to 19.95%)

Post-Transaction Holding: Strides' holding will reduce to 19.95%

Counterparty/Buyer: Consortium led by Ascent Capital (specifically Ascent Growth Trust through investment manager Ascent Capital Advisors India Private Limited) along with co-investor Vintage Classic Limited

Mode of Consideration: Cash

Valuation or Price Basis: Independent valuation conducted by a SEBI-registered merchant banker

Rationale for Disinvestment: Strategic investment to unlock value and enable access to external capital to support Pivot Path's next phase of growth

Impact on the Company: Pivot Path shall be reclassified as an Associate Company post-transaction

Business Profile of Target Entity:

  • Originated within Arco Lab Private Limited, Strides' Global Capability Centre (GCC)
  • Developed capabilities across life sciences consulting, digital transformation, quality and compliance, and technology-enabled operational services
  • Evolved into an independent platform serving industry-leading pharmaceutical and life sciences customers
  • Business was carved out into Pivot Path pursuant to a Scheme of Arrangement approved by NCLT in May 2026

Financial Contribution (FY 2025-26 post-demerger):

  • Consolidated Turnover: Rs. 1,447 million (including revenues for services rendered to Strides), contributing 3% to Strides Turnover
  • Consolidated Networth: Rs. 360 million, contributing 1% to Strides Networth
  • Standalone Networth: Rs. 100 million, contributing ~0.3% to Strides Networth
  • Standalone Turnover: Nil

Related Party Status: No. Investors do not belong to the Promoter, Promoter Group or Group Companies of Strides Pharma Science Limited

Transaction Structure:

  • Sale of Shares by Strides: Aggregate consideration of ~Rs. 1,000 million (Rs. 750 million payable at initial closing; Rs. 250 million payable on first anniversary of closing)
  • Primary Infusion into Pivot Path: Rs. 500 million by Ascent Capital to accelerate growth
  • Resultant Capital Structure: Strides 19.95%, Investors 65.05%, ESOP Pool 15%

Approvals Required: Already approved by Board of Directors on June 27, 2026

Indicative Timeline:

  • Definitive agreements expected before June 30, 2026
  • Sale of shares completion expected by June 30, 2026
  • Primary infusion completion expected by July 31, 2026

Other Updates

  • Board meeting was held on June 27, 2026, commencing at 15:00 hrs IST and concluding at 15:50 hrs IST
  • No other disclosures are present in the document